TBPH
Theravance Biopharma, Inc.Company Information
- Company Name
- Theravance Biopharma, Inc.
- CIK
- CIK0001583107
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- TBPH: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- TBPH
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-08-07
- Last sale
- 2026-09-15
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 206,626
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 46,448,213
- Shares outstanding
- 51,667,000
- Ownership
- 89.90%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- 0.95%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 220 | 288 | 168 | 175 | 282 | 111 | 38 | 23 | 46 | 54 | 40 | 72 | ||||||
| Available For Sale Securities Debt Securities Current | 168 | 107 | 148 | 155 | 57 | 20 | 51 | 68 | 50 | 46 | 63 | 62 | ||||||
| Other Prepaid Expense Current | 9 | 7 | 8 | 7 | 6 | 4 | 4 | 8 | 6 | 8 | 12 | 9 | ||||||
| Assets Current | 417 | 418 | 418 | 355 | 366 | 150 | 161 | 116 | 119 | 124 | 134 | 162 | ||||||
| Available For Sale Securities Debt Securities Noncurrent | - | - | 11 | 3 | - | - | - | - | - | - | - | - | ||||||
| Property Plant And Equipment Net | 5 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 9 | 9 | 9 | ||||||
| Operating Lease Right Of Use Asset | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 32 | 35 | 36 | 38 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 25 | 25 | 25 | 25 | 26 | 14 | 12 | 7 | 8 | 8 | 8 | 10 | ||||||
| Assets | 470 | 472 | 486 | 415 | 426 | 344 | 354 | 356 | 362 | 371 | 382 | 414 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 3 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | ||||||
| Employee Related Liabilities Current | 8 | 9 | 13 | 10 | 7 | 5 | 7 | 8 | 6 | 4 | 6 | 7 | ||||||
| Operating Lease Liability Current | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 4 | 4 | 4 | 4 | 10 | ||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Accrued Income Taxes Current | - | 5 | 5 | 4 | 27 | 6 | 6 | - | - | - | - | - | ||||||
| Other Accrued Liabilities Current | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | ||||||
| Liabilities Current | 31 | 32 | 38 | 37 | 55 | 32 | 32 | 23 | 23 | 22 | 25 | 25 | ||||||
| Operating Lease Liability Noncurrent | 28 | 30 | 32 | 34 | 36 | 37 | 39 | 41 | 42 | 44 | 45 | 41 | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 5 | 5 | 5 | 6 | 8 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | 0 | ||||||
| Additional Paid In Capital | 1,160 | 1,155 | 1,156 | 1,153 | 1,149 | 1,145 | 1,141 | 1,136 | 1,131 | 1,126 | 1,122 | 1,147 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | -0 | - | 0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -870 | -865 | -860 | -921 | -924 | -979 | -966 | -950 | -937 | -921 | -909 | -901 | ||||||
| Stockholders Equity | 290 | 291 | 297 | 233 | 225 | 166 | 176 | 186 | 194 | 205 | 213 | 246 | ||||||
| Liabilities And Stockholders Equity | 470 | 472 | 486 | 415 | 426 | 344 | 354 | 356 | 362 | 371 | 382 | 414 | ||||||
Preferred Stock Number Of Shares Par Value And Other Disclosures | ||||||||||||||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Common Stock Number Of Shares Par Value And Other Disclosures | ||||||||||||||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 52 | 52 | 51 | 51 | 50 | 50 | 49 | 49 | 49 | 49 | 48 | 51 | ||||||
| Shares Outstanding | 52 | 52 | 51 | 51 | 50 | 50 | 49 | 49 | 49 | 49 | 48 | 51 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTheravance Biopharma, Inc. (TBPH) — SEC Financial Statements & Analysis
Theravance Biopharma, Inc. (TBPH) is a pharmaceutical preparations company, incorporated in CA. Theravance Biopharma, Inc. trades on Nasdaq as: TBPH. Theravance Biopharma, Inc. (TBPH)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Theravance Biopharma, Inc. carries a market cap of $878.34M, a P/E ratio of 16.32x, a P/B ratio of 3.03x, a P/S ratio of 8.42x, an enterprise value of $657.74M, and an EV/EBITDA multiple of -23.65x. On profitability, it posts a gross margin of 103.95%, an operating margin of -26.67%, a net margin of 51.58%, a Return on Equity (ROE) of 20.91%, a Return on Assets (ROA) of 12.01%, and a Return on Invested Capital (ROIC) of -254.51%. Per share, it reports EPS of $1.04, diluted EPS of $1.04, free cash flow per share of $1.04, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 35.11% year-over-year, net income growth of 312.92% year-over-year, and EPS growth of 301.01% year-over-year. On the balance sheet, it maintains a current ratio of 13.54x, a quick ratio of 13.54x, working capital of $385.90M, a debt-to-equity ratio of 0.11x, a debt ratio of 0.07, an interest coverage ratio of -24.08x, free cash flow of $53.70M (TTM), and net debt of $-220.60M. Figures sourced from SEC EDGAR.
- Market Cap
- $878.34M
- P/E TTM
- 16.32x
- EPS TTM
- $1.04
- P/B TTM
- 3.03x
- ROE TTM
- 20.91%
- ROA TTM
- 12.01%
- Debt To Equity
- 0.11x
- Free Cash Flow TTM
- $53.70M
- Net Revenue TTM Growth 1Y
- 35.11%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Theravance Biopharma, Inc. in?
Theravance Biopharma, Inc. (TBPH) operates in the Pharmaceutical Preparations industry.
What exchange does TBPH trade on?
Theravance Biopharma, Inc. (TBPH) trades on the Nasdaq.
Where is Theravance Biopharma, Inc. incorporated?
Theravance Biopharma, Inc. is incorporated in CA.
When was Theravance Biopharma, Inc. (TBPH)'s most recent SEC filing?
Theravance Biopharma, Inc. (TBPH)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is TBPH's market cap?
Theravance Biopharma, Inc. (TBPH) has a market capitalization of $878.34M as of 2026-06-30.
What is TBPH's P/E ratio?
Theravance Biopharma, Inc. (TBPH)'s trailing twelve month P/E ratio is 16.32x as of 2026-06-30.
What is TBPH's EPS (earnings per share)?
Theravance Biopharma, Inc. (TBPH)'s trailing twelve month EPS is $1.04 as of 2026-06-30.
What is TBPH's ROE (return on equity)?
Theravance Biopharma, Inc. (TBPH)'s trailing twelve month Return on Equity (ROE) is 20.91% as of 2026-06-30.
What is TBPH's ROA (return on assets)?
Theravance Biopharma, Inc. (TBPH)'s trailing twelve month Return on Assets (ROA) is 12.01% as of 2026-06-30.
What is TBPH's ROIC (return on invested capital)?
Theravance Biopharma, Inc. (TBPH)'s trailing twelve month Return on Invested Capital (ROIC) is -254.51% as of 2026-06-30.
What is TBPH's EV/EBITDA?
Theravance Biopharma, Inc. (TBPH)'s trailing twelve month EV/EBITDA is -23.65x as of 2026-06-30.